Essential reading for the healthcare business
Remember me:
Skip Navigation LinksHealthInvestor article
Axis-Shield resists new Alere takeover attempt

UK-based diagnostics company Axis-Shield has urged shareholders to resist a fresh takeover attempt by US rival Alere.

In a statement today, Alere repeated its offer to Axis-Shield’s shareholders of 460 pence per share, which was formally made on 5 August. The offer, rejected by the Axis-Shield board, values the business at £230 million.

Alere announced today that it is lowering the threshold of its bid, which had been set at 90% of shareholder acceptance. The company said it now required more than 50% of voting rights, giving it the option of becoming a majority shareholder in Axis-Shield.

The US company also warned that if its offer were to lapse by a deadline of 10 October, “there is a strong possibility that Axis-Shield's share price would fall significantly below its current share price, particularly as no other potential bidder has announced its interest publicly”.

Alere said it was also looking at “alternative acquisitions, particularly in light of current valuations and market conditions”, and that it didn’t necessarily have to acquire Axis-Shield in order to achieve its “strategic objectives”.

In response, Axis-Shield’s board said it was “disappointed” that Alere had not taken notice of the “firm rebuttal” from shareholders to its offer, which it said was clear by the less than 1% level of acceptances that was disclosed in an Alere announcement on 16 September.

“The board has been more than willing to engage with Alere if Alere were to put a proposal to the board that fairly reflected the fundamental value of Axis-Shield. To date, no such proposal has been received from Alere,” said an Axis-Shield statement.

“The company has made excellent progress in the first half of the year and is on track to deliver for the second half of the year. The company believes that Alere is making a highly opportunistic offer in order to try and acquire Axis-Shield on the cheap.”

The 460 pence per share offer price represents a premium of 37% on the closing share price of 335 pence on 5 July 2011 – the last business day before Alere revealed it was considering an approach.

Posted on: 26/09/2011

Latest news stories

NHS England will fund the recruitment of 240 pharmacists and pharmacy technicians to work across care homes in England, as part of its ‘Refreshing NHS Plans for 2018-19’ scheme.
The government’s spring statement did not promise additional funding for health or social care, but Philip Hammond indicated that a rise may be granted in the autumn.
Nordic Capital Fund IX has acquired OberScharrer Group, a German ophthalmology provider, from owners Palamon Capital Partners.
Specialist care provider CMG, which is led by Chai Patel’s Court Cavendish management company, has hired Rothschild to find a buyer, HealthInvestor UK understands.
HCA Healthcare UK has announced it will open two further urgent care centres in the spring in response to its busiest winter yet.


Christie + Co

my images

interview: Adrian Stevensen
One Healthcare CEO Adrian Stevensen tells Ploy Radford how the new provider is overcoming the barriers to entry in the UK private hospital market
Read more

private finance initiative

The collapse of Carillion may have scuppered PF2's chances of survival. Mark Hellowell investigates
Read more

HealthInvestor blog
Spire’s new boss has unveiled his plans to restore the hospital group’s ailing fortunes and share price

Click here to view the Editor's blog

Pauline Issard recounts how she harnessed technology to combat frustrations with equine health issues
BGF has backed a one-of-a-kind business bridging the gap between hospitals with blocked beds and social care providers
A new IVF clinic from the team behind CREATE Fertility plans to make treatment more affordable, transparent and accessible, with a ‘shoebox’ technique at its core. Sarah Williams speaks to abc ivf chief executive Praful Nargund
The collapse of Carillion may have scuppered PF2’s chances of survival. Mark Hellowell investigates
Successive governments have tinkered with the country’s troubled health and social care system to little avail. Does this summer’s green paper herald a change though, asks David Brindle

Click here to search all feature articles